A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: A study of the PMH phase II consortium

Journal of Thoracic Oncology

Volumn 4, Issue 9, 2009, Pages 1163-1169

  Leighl, Natasha B ^a,b   Laurie, Scott A ^a,c   Chen, Xueyu E ^a,b   Ellis, Peter ^a,d   Shepherd, Frances A ^a,b   Knox, Jennifer J ^a,b   Goss, Glenwood ^a,c   Burkes, Ronald L ^a,e   Pond, Gregory R ^a,b,f   Dick, Christopher ^a,b   Yen, Yun ^g   Zwiebel, James A ^h   Moore, Malcolm J ^a,b  

^a Princess Margaret Hospital Phase 2 Consortium   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d JURAVINSKI CANCER CENTRE   (Canada)

^e MOUNT SINAI HOSPITAL   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antisense oligonucleotide; Docetaxel; GTI 2040; Lung cancer; R2 subunit; Ribonucleotide reductase; Second line

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; ANTIRETROVIRUS AGENT; DEXAMETHASONE; DOCETAXEL; GTI 2040; HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BACTEREMIA; BLEEDING; BONE MARROW; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CATHETER THROMBOSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; DRUG INFUSION; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GLUCOSE BLOOD LEVEL; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HYPERGLYCEMIA; INFECTION; LEUKOCYTE COUNT; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; ORGAN; PERFORMANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; SEPSIS; SIDE EFFECT; THROMBOCYTE; UROSEPSIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; TAXOIDS;

EID: 69549105776     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181a949b2     Document Type: Article

References (22)

1. American Cancer Society. American Facts and Figures 2006. Atlanta: American Cancer Society, 2006.
2. Canadian Cancer Society/National Cancer Institute of Canada: Canadian Cancer Statistics 2009. Toronto, Canada, 2009.
3. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103. (Pubitemid 30324363)
4. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
5. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
6. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
7. Nocentini G. Ribonucleotide reductase inhibitors: new strategies for cancer therapy. Crit Rev Oncol Hematol 1996;22:89-126. (Pubitemid 26083042)
8. Cory JG. Ribonucleotide reductase as a chemotherapeutic target. Adv Enzyme Regul 1988;27:437-455.
9. Fan H, Villegas C, Huang A, Wright JA. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanism of cellular transformation. Cancer Res 1998;58:1650-1653. (Pubitemid 28215087)
10. Huang A, Fan H, Taylor WR, Wright JA. Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability. Cancer Res 1997;47:4876-4881. (Pubitemid 27468997)
11. Synthetic phosphorothioated 20-mer oligonucleotide GTI-2040. Investigator's Brochure, edition number 3. November 29, 2004.
12. Desai AA, Schilsky RL, Young A, et al. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol 2005;16:958-965. (Pubitemid 40903923)
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
14. Zhang W, Leighl N, Zawisza D, Moore MJ, Chen EX. Determination of GTI-240, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid-liquid extractions. J Chromatograph B 2005;829:45-49. (Pubitemid 41773463)
15. Juhasz A, Vassilakos A, Chew HK. Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. Oncol Rep 2006;15:1299-1304.
16. Simon, R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10. (Pubitemid 19099520)
17. Wei X, Dai G, Marcucci G, et al. A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices. Pharm Res 2006;23:1251-1264. (Pubitemid 43946147)
18. Klisovic RB, Blum W, Wei X, et al. A phase I study of GTI-2040, an antisense to ribonucleotide reductase (RNR) in combination with highdose cytarabine (HiDAC) in relapsed or refractory acute myeloid leukemia (AML): pharmacokinetics (PK), pharmacodynamic (PD) and clinical results. Blood (ASH Annual Meeting Abstracts) 2009;106: Abstract 2790.
19. Lee Y, Avolio T, Feng N, et al. Determination of optimized administration scheduleof GTI-2040 and docetaxel combination treatment for NSCLC cells in vitro and in vivo [abstract]. In: Proceedings of American Association for Cancer Research Annual Meeting, Los Angeles, CA. Philadelphia, PA: AACR, 2007, April 14-18; Abstract 675.
20. Paz-Ares L, Douillard JY, Koralewski P, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2006;24:1428-1434. (Pubitemid 46622009)
21. Rudin CM, Kozloff M, Hoffman PC, et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004;22:1110-1117. (Pubitemid 41095045)
22. Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002;13:539-545. (Pubitemid 34461136)